María A. Gomis-Font

Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients.

A. Oliver, X. Mulet, R. Cantón, 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Emergence of Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308

A. Oliver, C. López-Causapé, M. Ojeda-Vargas, 2019, Antimicrobial Agents and Chemotherapy.

In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.

A. Oliver, C. Juan, B. Moyá, 2020, The Journal of antimicrobial chemotherapy.

Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump

A. Oliver, J. Vila, X. Mulet, 2021, Antimicrobial agents and chemotherapy.

In Vivo Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections

A. Oliver, X. Mulet, C. López-Causapé, 2021, Antimicrobial agents and chemotherapy.

Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.

A. Oliver, C. Juan, B. Moyá, 2022, The Journal of antimicrobial chemotherapy.